| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P50 | author | Felipe Prosper | Q37835050 |
| Xabier Agirre | Q40931651 | ||
| Leire Garate | Q114300720 | ||
| P2093 | author name string | Antonio Torres | |
| Francisco Cervantes | |||
| Anabel Heiniger | |||
| Lucia Cordeu | |||
| Antonio Jimenez-Velasco | |||
| Jose Roman-Gomez | |||
| Juan A Castillejo | |||
| Edurne San Jose-Eneriz | |||
| German Navarro | |||
| P2860 | cites work | The development of imatinib as a therapeutic agent for chronic myeloid leukemia | Q35993288 |
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| Demethylation of MAGE promoters during gastric cancer progression | Q36696751 | ||
| Expression of testicular genes in haematological malignancies | Q38273769 | ||
| Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma | Q38352763 | ||
| Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma | Q38468024 | ||
| SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically | Q40368383 | ||
| Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation | Q40405984 | ||
| Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. | Q40479861 | ||
| Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. | Q40599799 | ||
| HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes | Q40783989 | ||
| Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 | ||
| Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation | Q28242705 | ||
| Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer | Q28306838 | ||
| Cancer/testis antigens, gametogenesis and cancer | Q29616129 | ||
| Induction of Tumors in Mice by Genomic Hypomethylation | Q29618551 | ||
| Identification of a putative RNA helicase in E.coli | Q34100255 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial | Q34396079 | ||
| A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. | Q34747837 | ||
| Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. | Q35120932 | ||
| Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant | Q35319290 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| The biology of CML blast crisis | Q35675089 | ||
| Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen | Q41870799 | ||
| Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression | Q43718797 | ||
| Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. | Q43941032 | ||
| Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia | Q44500993 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells | Q51039333 | ||
| Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential | Q74463090 | ||
| Frequent expression of HAGE in presentation chronic myeloid leukaemias | Q78427205 | ||
| BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia | Q83894937 | ||
| P433 | issue | 2 | |
| P921 | main subject | chronic myeloid leukemia | Q729735 |
| P304 | page(s) | 153-162 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Haematologica | Q5638209 |
| P5824 | retracted by | Retraction: Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia | Q93560280 |
| P1476 | title | Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia | |
| P478 | volume | 92 |
| Q49505087 | Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response |
| Q84076645 | Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome |
| Q39966416 | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo |
| Q37517575 | Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. |
| Q39725130 | Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells |
| Q38288522 | Cancer/testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells |
| Q38360697 | Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. |
| Q37682934 | Circumventing immune tolerance through epigenetic modification |
| Q87537917 | Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer |
| Q39013117 | DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia |
| Q37424883 | DNA hypomethylation in the origin and pathogenesis of human diseases |
| Q34632716 | Derepression of Cancer/Testis Antigens in cancer is associated with distinct patterns of DNA Hypomethylation |
| Q45891499 | Elevated expression of cancer/testis antigen FSIP1 in ER-positive Breast Tumors |
| Q36786757 | Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103 |
| Q57570339 | Epigenetically regulated tumor-associated antigens in melanoma |
| Q57570341 | Epigenetically-Regulated Therapeutic Tumor-Associated Antigens |
| Q26823403 | Epigenomics of leukemia: from mechanisms to therapeutic applications |
| Q33613602 | HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer |
| Q41516658 | HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis |
| Q41963907 | HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. |
| Q37810114 | Hodgkin’s lymphoma: current treatment strategies and novel approaches |
| Q34046541 | Immunological off-target effects of imatinib |
| Q37326104 | Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells |
| Q26824575 | Linking epithelial-to-mesenchymal-transition and epigenetic modifications |
| Q38966088 | Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells |
| Q38093446 | Molecular and cellular pathogenesis of melanoma initiation and progression. |
| Q88716389 | Nature of tumour rejection antigens in ovarian cancer |
| Q36953073 | Novel therapies in myeloma |
| Q27853016 | Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells |
| Q33433199 | Profile analysis and prediction of tissue-specific CpG island methylation classes |
| Q34111803 | Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine. |
| Q80979924 | Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia |
| Q34097335 | Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. |
| Q90429907 | Targeting DNA Hypomethylation in Malignancy by Epigenetic Therapies |
| Q90720247 | The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia |
| Q43855142 | The Methylation Status of theDDX43Promoter in Chinese Patients with Chronic Myeloid Leukemia |
| Q37849976 | The biology of cancer testis antigens: putative function, regulation and therapeutic potential |
| Q37406014 | Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? |
| Q37848203 | Tumour-associated antigens: considerations for their use in tumour immunotherapy. |
| Q54427222 | Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. |
| Q38998990 | Wanted DEAD/H or Alive: Helicases Winding Up in Cancers. |
| Q33994385 | β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation |
| Q93560280 | Retraction: Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia | main subject | P921 |
Search more.